|
NanoLogix Announces Study Confirms Identikits Detect
Common AIDS Infection Known as Mycobacterium Avium Complex
SHARON, Pa., April 21, 2005 -- NanoLogix, Inc., (Pink Sheets: IFEC), a
Nanobiotechnology company engaged in the research, development and
commercialization of technologies for the production of bacteria and disease
testing kits, alternative sources of fuel, cancer therapy and remediation of
toxic materials, announced the results of a study which confirms that
disseminated MAC and M. simiae disease exist among AIDS patients. The study
was recently published in the Indian Journal of Tuberculosis (Indian J
Tuberc 2005; 52:21-26), and a presentation made at the 58th National
Conference on Tuberculosis & Chest Diseases held in Mumbai from 1st to 4th
January, 2004. Click here for study:
http://www.biotechstocksignals.com/ifecstudy.pdf
NanoLogix's "Identikit" has shown great promise in detecting the presence of
Mycobacterium avium complex (MAC) infection. The methodology provides for
early detection of these pathogens in sputum and stool samples; thus
allowing for treatment before the infection spreads throughout the body.
Early detection of Mycobacterium avium complex (MAC) infection is rapidly
becoming important, especially for those with AIDS who are living longer due
to new methods of treatment. The study, conducted by a team in the
Department of Microbiology, Mahatma Gandhi Institute of Medical Sciences,
Sevagram between August 2001 and December 2002 was recently published. The
team has documented that Mycobacterium avium complex (MAC) infection was
present in several patients with AIDS through the testing of blood, sputum,
peritoneal fluid, and stool samples with various culturing, isolation and
identification techniques and methods. Out of 167 patients tested positive
for HIV, blood samples from 71 were cultured for mycobacteria and 67 of
these were also clinically diagnosed as cases of either pulmonary and/or
extrapulmonary tuberculosis. The high prevalence of MAC infection in AIDS
patients highlights the need for a worldwide mandate to test AIDS patients
using NanoLogix's Identikit.
NanoLogix recently announced that it has received notification from the U.S.
Food and Drug Administration Center for Devices and Radiological Health ("FDA"),
of registration of the company and its initial product line for biophasic
system devices. Because it was categorized as a medical device that did not
require the standard lengthy FDA approval process, NanoLogix is beginning
the production, marketing and commercializing of its Identikit biophasic
system devices to cultivate and identify certain pathogenic microorganisms
for medical purposes.
MAC is the primary bacterial infection associated with "wasting syndrome" of
HIV/AIDS patients and is the leading cause of death among these patients
worldwide. MAC is routinely resistant to anti-tuberculosis drugs and there
has been no standardized method for determining antibiotic sensitivity. In
HIV/AIDS patients, MAC is usually diagnosed after symptoms appear. The
diagnostic screen utilizes a blood test. At this time, mortality is very
high and time to death is estimated at four months. "With NanoLogix's
Identikits, MAC could be detected significantly sooner than expected for
normal culture techniques," stated Paul Hyman, Ph.D. Dr. Hyman is the
primary investigator in NanoLogix's ongoing validation studies.
"Dr. Hyman's validation of NanoLogix's patented technology and the
subsequent FDA registration clearly show that we can identify a costly
disease in a fraction of the time," commented Dr. Mitchell Felder, Chief
Executive Officer of NanoLogix. "These results may also have enormous
implications in the treatment of TB, AIDS and MAC sufferers, as
antibiotic-sensitivity tests can now be performed early enough to make a
difference in these patients," he added.
According to estimates from the UNAIDS/WHO AIDS Epidemic Update (December
2004), 37.2 million adults and 2.2 million children were living with HIV at
the end of 2004. This is more than 50% higher than the figures projected by
WHO in 1991 on the basis of the data then available. During 2004, some 4.9
million people became infected with the human immunodeficiency virus (HIV),
which causes AIDS.
The year also saw 3.1 million deaths from AIDS - a high global total,
despite antiretroviral (ARV) therapy, which reduced AIDS-related deaths in
the richer countries. Deaths among those already infected will continue to
increase for some years even if prevention programs manage to cut the number
of new infections to zero. However, with the HIV-positive population still
expanding the annual number of AIDS deaths can be expected to increase for
many years, unless early diagnosis and a more effective provision of ARV
medication begins to slow the death rate.
Published data shows that 30% of the individuals that have HIV/Aids have
Tuberculosis (TB). It has also been estimated by world health authorities
that more than 70 percent of AIDS patients harbor an MAC infection. It has
been shown that MAC also causes opportunistic infections among non-HIV
infected pediatric and elderly persons. NanoLogix's technology allows for
the rapid culturing and identification of MAC. It will also provide viable
treatment options by testing the particular strain's antibiotic sensitivity.
By using saliva or stool samples, this process could identify an infection
as much as 10 months before the bacterium could be found in blood samples
and well before symptoms begin.
Tuberculosis kills more people each year than all of the other infectious
diseases combined and millions of people will die this year because of TB.
Tuberculosis (TB) is a highly contagious disease transmitted through the air
contaminated with droplets released from the lungs. TB strikes people in
their most productive years, ages 15 to 44. Of the 2 billion people infected
with TB, 200 million worldwide will develop active TB and then be able to
infect others. The key to controlling the spread of TB is accurate and fast
diagnosis so that treatment can begin. Testing for TB has become mandatory
when related to immigration in most countries.
NanoLogix is very pleased with the sophisticated advances in its
Nanobiotechnology research and development efforts in its day-to-day
practice of medicine. A complete report on NanoLogix can be found at:
http://www.biotechstocksignals.com/ifec.pdf
About NanoLogix
NanoLogix, Inc., formerly known as InfectTech, Inc.
http://www.infectech.com, is a
technology application innovator of biogas products and services designed to
assist in worldwide energy independence and reduce pollution from renewable,
environmentally-friendly energy sources. NanoLogix is also engaged in the
research and development of diagnostic test kits designed to be used for the
rapid identification of infectious human diseases. The Company's patents
span the identification and antibiotic sensitivity testing of 34
disease-producing bacteria, including M. tuberculosis (TB), Mycobacterium
avium-intracellulare (MAI), pseudomonas, and nocardia. These bacteria are
cited as prominent causes of morbidity and mortality in patients with
cancer, cystic fibrosis, and AIDS. Additionally, NanoLogix owns a patent for
the nontoxic induction of apoptosis in cancer cells utilizing hydrophobic
hydrocarbons. Apoptosis is a method for inducing a genetically based
induction of "cell suicide" in cells. The Company's 31 patents can be viewed
by visiting
http://www.infectech.com/intellectual_property.php .
About Nanotechnology
The convergence of science, medicine and technology is on the cusp of
yielding extraordinary breakthroughs. Today, patents that were once designed
to identify bacteria have widespread applications across multiple markets.
At the heart of this convergence is nature. All things begin and end with
the building blocks of life. NanoLogix's portfolio of 31 patents have
yielded a method vital to the development of biophasic system devices
intended for medical purposes to cultivate and identify certain pathogenic
microorganisms. The devices contain one or more components that suppress the
growth of certain microorganisms while either promoting or not affecting the
growth of other microorganisms. The FDA registered devices aid in the
diagnosis of disease caused by the pathogenic microorganisms. Additional
areas include: a method for low cost hydrogen production, a genomic cancer
therapy and methods for cleaning up toxic environments using bioremediation.
NanoLogix's patents have nanotechnology applications in medical
drugs/devices, bio-defense sensors, hydrogen production, cancer treatment
and bioremediation. Nanotechnology applications include Biochips embedded in
small transportable devices for rapid bacteria identification of disease
causing pathogens, and Bio Micro Electro Mechanical Systems ("BioMEMS") for
rapid environmental microbial monitoring with bio-defense implications. Its
hydrogen bioreactor research is designed to assist in worldwide energy
independence and reduce pollution using renewable, environmentally-friendly
energy sources. NanoLogix's FDA registered diagnostic test kits are designed
to be used for the rapid identification of infectious human diseases and
identify 34 disease-producing bacteria, including Tuberculosis (TB),
Mycobacterium avium-intracellulare (MAI), Pseudomonas, and Nocardia. These
bacteria are cited as prominent causes of morbidity and mortality in
patients with cancer, cystic fibrosis, and AIDS, as well as in patients
undergoing surgery. Additionally, NanoLogix owns a patent for the nontoxic
induction of apoptosis in cancer cells utilizing hydrophobic hydrocarbons.
Apoptosis is a method for inducing a genetically based induction of "cell
suicide" in cells. It therefore serves as the foundation for cancer therapy.
NanoLogix's other patents include technology designed for use in the
bioremediation of contaminated soil and water.
This press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements regarding
the intent, belief or current expectations of NanoLogix, Inc., and members
of its management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from those
contemplated by such forward-looking statements. Important factors currently
known to management that could cause actual results to differ materially
from those in forward- statements include fluctuation of operating results,
the ability to compete successfully and the ability to complete
before-mentioned transactions. The company undertakes no obligation to
update or revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future operating
results.
SOURCE NanoLogix, Inc.
Dr. Mitchell S. Felder of NanoLogix, Inc., +1-724-346-1302
|
|
